GLOBO H targeting CAR T Cells: generation and preclinical activity in gastrointestinal cancer cell lines

Abstract Background Chimeric Antigen Receptor (CAR) T cell therapy has transformed the treatment of hematological malignancies, but its efficacy against solid tumors remains limited by several barriers, including the difficulty of identifying tumor-specific antigens that minimize on-target, off-tumor toxicities. Globo H is a tumor-associated glycosphingolipid expressed in several epithelial malignancies, including gastrointestinal cancers, and has limited expression in normal tissues. We investigated the preclinical activity of MBr1-derived Globo H-specific CAR T cells. Methods Peripheral blood T cells from healthy donors were engineered using SFG retroviral vectors encoding second-generation CARs comprising an MBr1-derived single-chain variable fragment, a FLAG tag, a CD8α hinge and transmembrane region, a CD3ζ signaling domain, and either CD28 (CAR CD28) or 41BB (CAR 41BB) costimulatory domain. Following ex-vivo expansion with IL-7 and IL-15, the products were characterized for antigen-dependent cytotoxicity, differentiation and inhibitory-receptor expression, including during six serial NCI-N87 tumor-cell challenges. Antitumor activity was evaluated in NSG mice bearing NCI-N87 gastric cancer or OE33 esophageal adenocarcinoma xenografts. Results Both CAR constructs recognized and killed Globo H–positive tumor cell lines, and maintained cytotoxic activity over six serial NCI-N87 challenges. Despite comparable cytotoxicity, the constructs exhibited different phenotypic profiles: CAR 41BB T cells were enriched for less differentiated populations, whereas CAR CD28 showed greater effector differentiation and more pronounced inhibitory-receptor co-expression, particularly among CD4 + CAR + cells. CAR 41BB T cells delayed tumor growth in NCI-N87 and OE33 xenografts without overt toxicity under the conditions tested. CAR CD28 administration was associated with severe systemic toxicity in the NCI-N87 model. Conclusion These findings provide preclinical evidence of antigen-dependent antitumor activity of Globo H-targeted CAR T cells in gastrointestinal cancer models. While the 4-1BB-based construct showed a favorable phenotypic profile and antitumor activity without overt toxicity in the models tested, the severe systemic toxicity observed with the CD28-based construct highlights the need for further investigation into the biological determinants of toxicity.

Authors

Institutions

Publication Details

Journal
Journal of Experimental & Clinical Cancer Research
Published
2026-11-13
DOI
https://doi.org/10.1186/s13046-026-03877-2
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

GLOBO H targeting CAR T Cells: generation and preclinical activity in gastrointestinal cancer cell lines

Filippo de Braud, Francesca De Santis, Marco Gentili, Marco Barella et al.
3 links
Journal of Experimental & Clinical Cancer Research
CAR-T cell therapy research
article

GLOBO H targeting CAR T Cells: generation and preclinical activity in gastrointestinal cancer cell lines

Filippo de Braud, Francesca De Santis, Marco Gentili, Marco Barella, Elena Luison, Chiara Costanza Volpi, F. Putti, Luca Roz, Massimo Di Nicola, Licia Rivoltini, Giancarlo Pruneri, Paolo Cappella, Mariangela Figini, Davide Tresoldi
article en

Abstract

Abstract Background Chimeric Antigen Receptor (CAR) T cell therapy has transformed the treatment of hematological malignancies, but its efficacy against solid tumors remains limited by several barriers, including the difficulty of identifying tumor-specific antigens that minimize on-target, off-tumor toxicities. Globo H is a tumor-associated glycosphingolipid expressed in several epithelial malignancies, including gastrointestinal cancers, and has limited expression in normal tissues. We investigated the preclinical activity of MBr1-derived Globo H-specific CAR T cells. Methods Peripheral blood T cells from healthy donors were engineered using SFG retroviral vectors encoding second-generation CARs comprising an MBr1-derived single-chain variable fragment, a FLAG tag, a CD8α hinge and transmembrane region, a CD3ζ signaling domain, and either CD28 (CAR CD28) or 41BB (CAR 41BB) costimulatory domain. Following ex-vivo expansion with IL-7 and IL-15, the products were characterized for antigen-dependent cytotoxicity, differentiation and inhibitory-receptor expression, including during six serial NCI-N87 tumor-cell challenges. Antitumor activity was evaluated in NSG mice bearing NCI-N87 gastric cancer or OE33 esophageal adenocarcinoma xenografts. Results Both CAR constructs recognized and killed Globo H–positive tumor cell lines, and maintained cytotoxic activity over six serial NCI-N87 challenges. Despite comparable cytotoxicity, the constructs exhibited different phenotypic profiles: CAR 41BB T cells were enriched for less differentiated populations, whereas CAR CD28 showed greater effector differentiation and more pronounced inhibitory-receptor co-expression, particularly among CD4 + CAR + cells. CAR 41BB T cells delayed tumor growth in NCI-N87 and OE33 xenografts without overt toxicity under the conditions tested. CAR CD28 administration was associated with severe systemic toxicity in the NCI-N87 model. Conclusion These findings provide preclinical evidence of antigen-dependent antitumor activity of Globo H-targeted CAR T cells in gastrointestinal cancer models. While the 4-1BB-based construct showed a favorable phenotypic profile and antitumor activity without overt toxicity in the models tested, the severe systemic toxicity observed with the CD28-based construct highlights the need for further investigation into the biological determinants of toxicity.

Journal of Experimental & Clinical Cancer Research
University of Milan (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Ministero della Salute, Regione Lombardia, Agenzia Italiana del Farmaco, Ministero della Salute
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon